Healthcare provider profile · identity verified

Niladri Das, MD

Family Practice · READING, PA · NPI 1275731689

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	388	113
Omeprazole	Omeprazole	230	67
Amlodipine Besylate	Amlodipine Besylate	178	62
Albuterol Sulfate Hfa	Albuterol Sulfate	165	63
Levothyroxine Sodium	Levothyroxine Sodium	151	42
Lisinopril	Lisinopril	139	50
Gabapentin	Gabapentin	123	41
Metoprolol Succinate	Metoprolol Succinate	121	34
Famotidine	Famotidine	112	36
Metformin Hcl Er	Metformin Hcl	110	37
Pantoprazole Sodium	Pantoprazole Sodium	104	27
Duloxetine Hcl	Duloxetine Hcl	100	23
Trazodone Hcl	Trazodone Hcl	99	30
Furosemide	Furosemide	94	26
Jardiance	Empagliflozin	83	25
Rosuvastatin Calcium	Rosuvastatin Calcium	82	28
Prednisone	Prednisone	81	51
Tamsulosin Hcl	Tamsulosin Hcl	81	29
Fluticasone Propionate	Fluticasone Propionate	80	31
Metformin Hcl	Metformin Hcl	80	27
Losartan Potassium	Losartan Potassium	77	30
Mirtazapine	Mirtazapine	74	25
Hydrochlorothiazide	Hydrochlorothiazide	69	30
Lorazepam	Lorazepam	68	18
Fluoxetine Hcl	Fluoxetine Hcl	67	18
Sertraline Hcl	Sertraline Hcl	67	19
Simvastatin	Simvastatin	64	23
Eliquis	Apixaban	60	15
Ozempic	Semaglutide	60	17
Metoprolol Tartrate	Metoprolol Tartrate	56	16
Mounjaro	Tirzepatide	54	suppressed
Buspirone Hcl	Buspirone Hcl	53	14
Ezetimibe	Ezetimibe	53	13
Pregabalin	Pregabalin	53	14
Escitalopram Oxalate	Escitalopram Oxalate	51	19
Doxycycline Hyclate	Doxycycline Hyclate	50	37
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	46	15
Pravastatin Sodium	Pravastatin Sodium	46	20
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	44	12
Trulicity	Dulaglutide	44	16
Montelukast Sodium	Montelukast Sodium	43	14
Clonazepam	Clonazepam	41	suppressed
Carvedilol	Carvedilol	39	13
Diclofenac Sodium	Diclofenac Sodium	39	17
Ipratropium Bromide	Ipratropium Bromide	37	11
Alendronate Sodium	Alendronate Sodium	36	11
Clopidogrel	Clopidogrel Bisulfate	36	13
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	36	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	35	15
Valacyclovir	Valacyclovir Hcl	35	suppressed
Xarelto	Rivaroxaban	35	11
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	32	14
Mupirocin	Mupirocin	32	21
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	31	11
Spironolactone	Spironolactone	30	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	30	19
Citalopram Hbr	Citalopram Hydrobromide	28	suppressed
Baclofen	Baclofen	26	suppressed
Tresiba Flextouch U-200	Insulin Degludec	26	suppressed
Alprazolam	Alprazolam	25	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	25	suppressed
Glipizide Er	Glipizide	25	suppressed
Oxycodone Hcl	Oxycodone Hcl	25	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	25	11
Warfarin Sodium	Warfarin Sodium	25	suppressed
Benazepril Hcl	Benazepril Hcl	24	suppressed
Paroxetine Hcl	Paroxetine Hcl	24	suppressed
Nystatin	Nystatin	23	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	23	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	22	19
Oxybutynin Chloride Er	Oxybutynin Chloride	22	suppressed
Propranolol Hcl	Propranolol Hcl	22	suppressed
Allopurinol	Allopurinol	21	suppressed
Azelastine Hcl	Azelastine Hcl	20	11
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	20	suppressed
Spiriva Respimat	Tiotropium Bromide	20	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	20	suppressed
Breo Ellipta	Fluticasone/Vilanterol	19	suppressed
Bupropion Xl	Bupropion Hcl	19	suppressed
Ondansetron Odt	Ondansetron	19	suppressed
Propranolol Hcl Er	Propranolol Hcl	19	suppressed
Topiramate	Topiramate	19	suppressed
Azithromycin	Azithromycin	18	14
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	18	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	18	suppressed
Naproxen	Naproxen	18	11
Potassium Chloride	Potassium Chloride	18	suppressed
Aripiprazole	Aripiprazole	17	suppressed
Cephalexin	Cephalexin	17	11
Finasteride	Finasteride	17	suppressed
Myrbetriq	Mirabegron	16	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	16	11
Chlorthalidone	Chlorthalidone	15	suppressed
Lactulose	Lactulose	15	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	15	suppressed
Memantine Hcl	Memantine Hcl	15	suppressed
Ondansetron Hcl	Ondansetron Hcl	15	suppressed
Ropinirole Hcl	Ropinirole Hcl	15	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	14	suppressed
Glimepiride	Glimepiride	14	suppressed
Hydrocortisone	Hydrocortisone	14	suppressed
Nifedipine Er	Nifedipine	14	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	13	suppressed
Meloxicam	Meloxicam	13	suppressed
Prazosin Hcl	Prazosin Hcl	13	suppressed
Vraylar	Cariprazine Hcl	13	suppressed
Celecoxib	Celecoxib	12	suppressed
Donepezil Hcl	Donepezil Hcl	12	suppressed
Incruse Ellipta	Umeclidinium Bromide	12	suppressed
Levetiracetam	Levetiracetam	12	suppressed
Lidocaine	Lidocaine	12	suppressed
Praluent Pen	Alirocumab	12	suppressed
Divalproex Sodium Er	Divalproex Sodium	11	suppressed
Emgality Pen	Galcanezumab-Gnlm	11	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Fiasp Flextouch	Insulin Aspart (Niacinamide)	11	suppressed
Levofloxacin	Levofloxacin	11	suppressed
Morphine Sulfate	Morphine Sulfate	11	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	11	suppressed
Nyamyc	Nystatin	11	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	11	suppressed
Tizanidine Hcl	Tizanidine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error